Binds Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor, Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 530/388.25)
-
Patent number: 7241578Abstract: The immunoassay method of this invention measures the content of a subject substance in a sample. The method includes the steps of: (a) preparing a mixed solution by mixing the sample and an antibody solution including a first monoclonal antibody and a second monoclonal antibody capable of specifically binding to the subject substance; and (b) measuring an optical property of the mixed solution. The first monoclonal antibody is capable of binding to a first epitope of the subject substance, and the second monoclonal antibody is capable of binding to a second epitope of the subject substance different from the first epitope. Each of the first and second epitopes exists singly in the subject substance.Type: GrantFiled: May 20, 2003Date of Patent: July 10, 2007Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Keiko Yugawa, Nobuyuki Shigetoh, Akihito Kamei, Tatsurou Kawamura
-
Publication number: 20070154479Abstract: The application disclose a method of preventing immune cells from binding to other cells, which includes contacting the immune cells and the other cells with a composition comprising Bst2 antagonist.Type: ApplicationFiled: June 20, 2006Publication date: July 5, 2007Inventors: Myung Kyung Kim, Jay Hang Chung, June-Young Park, Hyouna Yoo, Sang-Min Lee, Yoon-Seok Lee, Mison Koo, Sang-Ho Park, Juheng Lee, Young Mi Hur
-
Patent number: 7235643Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the affinity of monoclonal antibodies and monoclonal antibodies with increased affinity.Type: GrantFiled: September 13, 2002Date of Patent: June 26, 2007Assignee: Morphotek, Inc.Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
-
Patent number: 7214785Abstract: The present invention provides a human antibody against blood coagulation factor VIII (hereinafter also referred to as “FVIII”) and an antibody fragment that binds to human FVIII and specifically inhibits the coagulation activity of human FVIII. ScFv display phage libraries, prepared by using scFv DNAs constructed by random combinations of immunoglobulin VH chain genes and VL chain genes from lymphocytes from hemophilia A patients, is reacted with FVIII immobilized to a solid phase via anti-FVIII monoclonal antibody, and scFv clones capable of binding to FVIII are cloned to reveal VH and VL chains of FVIII-specific antibody.Type: GrantFiled: June 11, 2002Date of Patent: May 8, 2007Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Toshihiro Nakashima, Masato Yuguchi
-
Patent number: 7157085Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.Type: GrantFiled: March 2, 2004Date of Patent: January 2, 2007Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
-
Patent number: 7138116Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.Type: GrantFiled: November 7, 2002Date of Patent: November 21, 2006Assignee: Ajinomoto Co., Inc.Inventors: Man Sung Co, Maximiliano Vasquez
-
Patent number: 7132510Abstract: The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present invention includes a peptide or polypeptide comprising an Fv molecule, having a heavy variable chain comprising CDR3, CDR2 and CDR1 regions comprising the amino acid sequences SEQ ID NOS:8, 115 and 114, respectively.Type: GrantFiled: December 31, 2001Date of Patent: November 7, 2006Assignee: Bio-Technology General (Israel) Ltd.Inventors: Yocheved Hagay, Janette Lazarovits, Rachel Guy, Orly Lifshitz, Esther Szanton, Avigdor Levanon, Daniel Plaksin, Tuvia Peretz
-
Patent number: 7122324Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of C-terminal hGPIIb fragment of the platelet receptor GPIIb-IIIa in a body fluid sample are disclosed.Type: GrantFiled: September 3, 2004Date of Patent: October 17, 2006Assignee: The Scripps Research InstituteInventors: Mark H. Ginsberg, Andrew L. Frelinger, III, Edward F. Plow
-
Patent number: 7112327Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: May 27, 2005Date of Patent: September 26, 2006Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 7098036Abstract: Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as “dipsticks”. The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample.Type: GrantFiled: November 13, 1997Date of Patent: August 29, 2006Assignee: Okalahoma Medical Research FoundationInventors: Eugen Koren, Mirna Koscec
-
Patent number: 7083786Abstract: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.Type: GrantFiled: June 4, 2001Date of Patent: August 1, 2006Inventors: Jens Chr. Jensenius, Steffen Thiel
-
Patent number: 7067313Abstract: The present invention comprises ligands and methods of manufacture thereof as well as pharmaceutical preparations including the ligands. The ligands may be human or humanized monoclonal antibodies and fragments, derivatives and homologs thereof. These may exhibit an unforeseen “plateau effect”, i.e. the achievement of only a partial inactivation of a factor involved in hemostasis, in particular in the coagulation cascade, either individually or in combination even in molar excess. The ligands may bind to a factor or a complex of factors resulting in only partially impairing the function of a physiologically functional site of the said factor or factor complex even in molar excess. This makes the ligands particularly suitable for treating coagulation disorders and resulting thrombotic pathologic conditions while minimizing the risk of bleeding.Type: GrantFiled: July 13, 2000Date of Patent: June 27, 2006Assignee: D. Collen Research FoundationInventors: Marc G. Jacquemin, Jean-Marie R. Saint-Remy
-
Patent number: 7060268Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: GrantFiled: May 2, 2003Date of Patent: June 13, 2006Assignee: Genentech, Inc.Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Patent number: 7056509Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.Type: GrantFiled: February 24, 2003Date of Patent: June 6, 2006Assignee: Board of Regents The University of Texas SystemInventors: Philip E. Thorpe, Rolf A. Brekken
-
Patent number: 7049411Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.Type: GrantFiled: July 8, 2003Date of Patent: May 23, 2006Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Brigitte Devaux, Dan L. Eaton, Philip E. Hass, J. Kevin Judice, Daniel Kirchhofer, Shelley Suggett
-
Patent number: 7033590Abstract: An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.Type: GrantFiled: September 14, 2000Date of Patent: April 25, 2006Assignee: Baxter AktiengesellschaftInventors: Friedrich Scheiflinger, Randolf Kerschbaumer, Falko-Guenter Falkner, Friedrich Dorner, Hans-Peter Schwarz
-
Patent number: 7026456Abstract: The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.Type: GrantFiled: August 30, 2000Date of Patent: April 11, 2006Assignee: Hoffman-La Roche, Inc.Inventors: Maurice Kent Gately, David Howard Presky
-
Patent number: 7018627Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C—C chemokine designated “Macrophage Derived Chemokine” (MDC), and polypeptide fragments and analogs thereof. Also provided are materials and methods for the recombinant or synthetic production of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity.Type: GrantFiled: September 28, 1998Date of Patent: March 28, 2006Assignee: Icos CorporationInventors: Patrick W. Gray, David H. Chantry, Michael C. Deeley, Carol J. Raport, Ronald Godiska
-
Patent number: 6998469Abstract: The present invention comprises a method of purifying GPVI, GPVI peptides, cDNA and protein sequence, and methods for using GPVI and antibodies directed against GPVI.Type: GrantFiled: May 29, 2003Date of Patent: February 14, 2006Assignee: Otsuka America Pharmaceutical, Inc.Inventors: Narendra Nath Tandon, Bing Sun, Takashi Nakamura, Naomasa Yamamoto
-
Patent number: 6998468Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: March 23, 2001Date of Patent: February 14, 2006Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, Cecily R. Y. Sun, William N. C. Sun
-
Patent number: 6989241Abstract: A highly specific monoclonal antibody, produced by a hybridoma cell has been found. A new assay, highly specific for activated protein C (APC) has been developed which will permit rapid determination of APC levels in clinical situations.Type: GrantFiled: October 2, 2001Date of Patent: January 24, 2006Assignee: Oklahoma Medical Research FoundationInventors: Charles T. Esmon, Patricia C. Y. Liaw, Gary L. Ferrell
-
Patent number: 6964854Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.Type: GrantFiled: July 13, 2000Date of Patent: November 15, 2005Assignee: Science & Technology CorporationInventors: Gowthami M. Arepally, Walter Kisiel, Keiko Kamei, Shintaro Kamei
-
Patent number: 6960472Abstract: Monoclonal antibodies having high affinity for N-terminus pro brain natriuretic peptide (NT-proBNP) are described. The monoclonal antibodies are prepared against a synthetic peptide having the Sequence ID No. 1. Specifically, the monoclonal antibodies described are produced from two hybridoma cell lines, 6G11-F11-D12 and 1C3-E11-R9, deposited with the American Type Culture Collection under Accession Numbers PTA-4844 and PTA-4845 respectively. The monoclonal antibody antibodies can be used as reagents in an immunoassay system to identify blood, serum or plasma levels of NT-proBNP. Such an immunoassay system can be used for diagnosing and quantifying congestive heart failure (CHF).Type: GrantFiled: February 4, 2003Date of Patent: November 1, 2005Assignee: Ottawa Heart Institute Research CorporationInventor: Adolfo J. DeBold
-
Patent number: 6956107Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: March 29, 2001Date of Patent: October 18, 2005Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 6953667Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: GrantFiled: January 25, 2002Date of Patent: October 11, 2005Assignee: Human Genome Sciences, Inc.Inventors: Paul A. Moore, Steven M. Ruben, Henrik S. Olsen, Yanggu Shi, Craig A. Rosen, Kimberly A. Florence, Daniel R. Soppet, David W. LaFleur, Gregory A. Endress, Reinhard Ebner, George Komatsoulis, Roxanne D. Duan
-
Patent number: 6942977Abstract: Methods are described for the development of monoclonal antibodies to intrinsic factor and the application of said antibodies in the development of B12 immunoassays. In particular, antibodies are described that are capable of binding to intrinsic factor only in the absence of vitamin B12, and that are released from binding in the presence, and upon the binding, of vitamin B12 to intrinsic factor. Assays may be formatted such that either antibody or intrinsic factor is immobilized or labeled.Type: GrantFiled: May 28, 1993Date of Patent: September 13, 2005Assignee: Bio-Rad Laboratories, Inc.Inventors: Karel Newman, Jane Schmidt, Paul Wegfahrt
-
Patent number: 6936424Abstract: The invention provides a wide range of methods and compositions for detecting and treating breast cancer in an individual. Specifically, the invention provides target breast cancer-associated proteins, which permit a rapid detection, preferably before metastases occur, of breast cancer. The target breast cancer-associated protein may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of breast cancer in an individual. In addition, the invention provides methods utilizing the breast cancer-associated proteins either as targets for treating breast cancer or as indicators for monitoring the efficacy of such a treatment.Type: GrantFiled: November 10, 2000Date of Patent: August 30, 2005Assignee: Matritech, Inc.Inventors: Brynmor Watkins, Robert P. Szaro
-
Patent number: 6893831Abstract: The present invention provides an immunoassay for specifically measuring with high sensitivity PIVKA-II in serum or plasma through antigen-antibody reaction by adding an animal serum containing thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents. The immunoassay of the invention comprises the steps of adding thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents, and measuring PIVKA-II in serum or plasma.Type: GrantFiled: June 1, 2000Date of Patent: May 17, 2005Assignee: Sanko Junyaku Co., Ltd.Inventors: Motohito Kanashima, Tomohide Asai, Hiroki Takahashi, Yoshiyuki Asai
-
Patent number: 6869606Abstract: Biotinylated pharmacologically active agents and complexes containing same are disclosed. In particular, biotinylated-chemokines are described. The complexes further include an anti-biotin antibody that selectively binds to biotin. The complex can be dissociated by contact with free biotin. The complexes are particularly useful for enhancing an immune response to tumor cells and virus-infected cells, in vivo or in vitro.Type: GrantFiled: February 18, 2000Date of Patent: March 22, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventors: Walter Newman, Dominic Picarella, Dulce Soler
-
Patent number: 6866845Abstract: The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.Type: GrantFiled: August 30, 2000Date of Patent: March 15, 2005Assignee: The Regents of the University of MichiganInventors: Peter A. Ward, Markus Huber-Lang, Vidya Sarma
-
Patent number: 6858438Abstract: The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detection autoimmune antibodies.Type: GrantFiled: November 14, 1997Date of Patent: February 22, 2005Assignee: Stichting Voor De Technische WetenschappenInventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jozef Maria Hendrik Raats, Rene Michael Antonius Hoet, Gerardus Antonius Schellekens
-
Patent number: 6855508Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.Type: GrantFiled: August 5, 2002Date of Patent: February 15, 2005Assignee: Genentech, Inc.Inventors: David Tai Wai Fei, Kristen Tomita
-
Patent number: 6838250Abstract: The present invention relates to new CRP immunoassay compositions. The compositions include a low affinity anti-human CRP monoclonal antibody, and an antiidiotypic antibody raised against it. The invention further provides a method for obtaining antiidiotypic monoclonal antibody populations directed to an antibody that is specific for a high concentration, high molecular weight target antigen.Type: GrantFiled: March 29, 2001Date of Patent: January 4, 2005Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Edward R. Scalice, John L. Daiss
-
Patent number: 6835817Abstract: A monoclonal antibody has been developed which only specifically binds activated factor VII, and not factor VII, and which does not bind to an activated factor VII which is complexed with antithrombin III. This monoclonal antibody is isolated from the hybridoma cell line DSM ACC 2332. It can be used for qualitatively and quantitatively detecting factor VIIa in body fluids, blood coagulation preparations or the intermediate stages in the production of these preparations, on cell surfaces or in tissues, and can also be used as a humanized monoclonal antibody in therapeutic preparations.Type: GrantFiled: August 23, 2002Date of Patent: December 28, 2004Assignee: ZLB Behring GmbHInventors: Jürgen Römisch, Wiegand Lang, Annette Feussner, Joachim Röder
-
Patent number: 6835545Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.Type: GrantFiled: April 16, 2001Date of Patent: December 28, 2004Assignee: President and Fellows of Harvard CollegeInventor: Jose Halperin
-
Publication number: 20040259157Abstract: The present invention relates to early secretory pathway molecules, in particular to the MCFD2 (multiple coagulation factor deficiency 2) protein, and nucleic acids encoding the MCFD2 protein. The present invention provides assays for the detection of MCFD2 and for MCFD2 polymorphisms and mutations associated with disease states and provides screening assays for the identification and use of compounds that alter MCFD2 activity and/or biological pathways involving MCFD2.Type: ApplicationFiled: February 18, 2004Publication date: December 23, 2004Inventors: David Ginsburg, Bin Zhang, Randal J. Kaufman
-
Publication number: 20040253240Abstract: The present invention relates to novel vaccine therapies, and prophylactic treatments of atherosclerotic diseases. Accordingly there is provided, immunogens comprising specific fragments or derivatives of Apolipoprotein C-III (ApoCIII). The vaccines of the present invention, comprising said immunogens, are potent in the prevention, or reduction, of atherosclerotic plaque formation over prolonged periods of time, thereby reducing the potential of atheroslerosis leading to coronary or cerebrovascular disease. Also provided are methods of treating or preventing atherosclerosis by active vaccination, or passive vaccination through administration to a patient of an antibody that is capable of binding to the specific fragments of ApoCIII. Specific monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the immunogens of the present invention in medicine, and methods of their production.Type: ApplicationFiled: February 27, 2004Publication date: December 16, 2004Inventors: Jean-Charles Fruchart, Rene Meykens, Philippe Monteyne
-
Patent number: 6830896Abstract: The present invention provides a process and regent for analyzing annexin-V, wherein the measurement of a concentration of annexin-V can be easily carried out without need for addition of chemicals for inhibiting the bonding of various proteins with calcium ion and for adjusting a specimen solution to the specimen at a measuring stage, and a process and medicine for diagnosing an internal organ disorder based on the analyzing process and regent. A urine is brought into contact with an anti-annexin-V monoclonal antibody to perform an antigen-antibody reaction of annexin-V in the urine with the anti-annexin-V monoclonal antibody, thereby forming an annexin-V antigen/anti-annexin-V monoclonal antibody complex, and the amount of the formed annexin-V antigen/anti-annexin-V monoclonal antibody complex is quantitatively measured.Type: GrantFiled: November 15, 2002Date of Patent: December 14, 2004Inventors: Noboru Kaneko, Ryuko Matsuda, Tadahiro Kajita
-
Publication number: 20040247599Abstract: The present invention relates to modulators of P2Y10. Various modulators are disclosed, including an antibody that binds specifically to P2Y10. The present invention also relates to methods of activating resting T lymphocytes and inhibiting the proliferation of activated T lymphocytes. Methods of upregulating trascription of P2Y10 mRNA in a resting T lymphocyte, methods of inducing expression of P2Y10 on the surface of a resting T lymphocyte and methods of activating a T lymphocyte are disclosed. Also disclosed are pharmaceuticals and methods of treating an immune disease.Type: ApplicationFiled: May 13, 2004Publication date: December 9, 2004Inventors: James R. Burke, Violetta Iotzova
-
Publication number: 20040242851Abstract: The present invention is directed to production of antigen-binding proteins that bind specifically to an extracellular domains of two different VEGF receptors, The bispecific antigen-binding proteins block activation of the VEGF receptors and are used to reduce or inhibit VEGF-induced cellular functions such as mitogenesis of vascular endothelial cells and migration of leukemia cells. The antigen-binding proteins of the present invention can be monovalent or multivalent, have antigen-binding sites consisting of immunoglobulin heavy chain and light chain variable domains and may further include immunoglobulin constant domains.Type: ApplicationFiled: July 8, 2004Publication date: December 2, 2004Inventor: Zhenping Zhu
-
Publication number: 20040242468Abstract: The present invention features a novel human protein (ANK), nucleotide sequences encoding human ANK, and assays for ANK activity, including assays to identify therapeutics and diagnostic assays, e.g., for susceptibility to diseases such as arthritis. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human ANK. The present invention also relates to antibodies that bind specifically to a human ANK, and methods for producing human ANK polypeptides.Type: ApplicationFiled: December 2, 2002Publication date: December 2, 2004Inventors: David Kingsley, Michelle Deanetta Johnson, Andrew Manlap Ho
-
Publication number: 20040242513Abstract: Splice variants of a human “TUB” antisense gene have been discovered, which overlap with human TUB and murine “tub” in antisense orientation. The overlapping portions suggest a regulatory/attenuation effect, due to RNA-RNA-interaction. These findings demonstrate that these TUB antisense constructs can regulate weight disorders, such as obesity, and progressive sensorineural degeneration phenotypes of the central nervous system. Accordingly, the invention provides therapeutic methods utilizing these constructs, as well as methods for identifying compounds that can therapeutically treat weight disorders.Type: ApplicationFiled: May 7, 2004Publication date: December 2, 2004Inventors: Dirk Prawitt, Bernhard Ulrich Zabel, Thomas Brueckmann, Erwin Schmidt, Andreas Winterpacht, Thomas Hankeln
-
Publication number: 20040234524Abstract: An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR sequence or sequence equivalent thereto to osteopontin or its fragment. This antibody is useful in remedies for autoimmune diseases, remedies for rheumatism and remedies for rheumatoid arthritis. Also, a method of treating autoimmune disease, rheumatism or rheumatoid arthritis is provided. This antibody is useful in diagnostics and a diagnostic method for rheumatism too.Type: ApplicationFiled: May 20, 2004Publication date: November 25, 2004Inventors: Toshimitsu Uede, Shigeyuki Kon, Yukihiko Saeki, Yasuyuki Yokosaki, Masaki Noda, Nobuchika Yamamoto
-
Publication number: 20040237124Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: ApplicationFiled: December 24, 2003Publication date: November 25, 2004Inventors: Jaume Pons, Arnon Rosenthal
-
Publication number: 20040235058Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.Type: ApplicationFiled: June 23, 2004Publication date: November 25, 2004Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, Marek Kubin, Richard Jeffrey Armitage
-
Publication number: 20040229301Abstract: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.Type: ApplicationFiled: April 5, 2004Publication date: November 18, 2004Inventor: Baiyang Wang
-
Publication number: 20040229282Abstract: Disclosed is a method for treating blood coagulation in a mammal that has or is suspected of having septic shock syndrome. In one embodiment, the method includes administering to the mammal an effective amount of an antibody that binds tissue factor in a way that excludes Factor X (FX) binding. The invention has a wide range of useful applications including use to inhibit unwanted blood coagulation associated with sepsis.Type: ApplicationFiled: January 22, 2004Publication date: November 18, 2004Applicant: Sunol Molecular CorporationInventors: Hing C. Wong, Jin-an Jiao
-
Publication number: 20040223967Abstract: A purpose of the present invention is to clarify the mechanism of the intrinsic clotting system which is induced by activation of blood coagulation factor IX by erythrocyte membrane, and to clarify the structure of a factor which activates blood coagulation factor IX by isolating and identifying the factor.Type: ApplicationFiled: December 12, 2003Publication date: November 11, 2004Applicant: RIKENInventors: Makoto Kaibara, Hiroki Iwata, Koji Takio, Naoshi Dohmae
-
Publication number: 20040208876Abstract: The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.Type: ApplicationFiled: April 15, 2004Publication date: October 21, 2004Inventors: Kyung Jin Kim, Yi-Chi Su, Lihong Wang
-
Patent number: RE39138Abstract: The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, on Apr. 27, 1994. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.Type: GrantFiled: December 16, 1999Date of Patent: June 20, 2006Assignee: Alteon IncorporatedInventors: Henry W. Founds, Homayoun Sadeghi